Trial Radar IA | ||
|---|---|---|
Lo studio clinico NCT02912728 (SENCE) per Diabete mellito di tipo 1 è completato. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui. | ||
Un studio corrisponde ai criteri del filtro
Vista a schede
Strategies to Enhance New CGM Use in Early Childhood (SENCE) 143
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT02912728 (SENCE) è stata uno studio interventistico per Diabete mellito di tipo 1, attualmente completato. Avviato il 30 gennaio 2017, prevedeva di arruolare 143 partecipanti. Sotto la guida di Jaeb Center for Health Research, si è concluso il 30 giugno 2019. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 5 ottobre 2020.
Sommario breve
The primary objective of this study is to compare the efficacy and safety of CGM alone and CGM combined with a family behavioral intervention with a control group using home blood glucose monitoring (BGM) alone.
Descrizione dettagliata
Although prior studies have not demonstrated that continuous glucose monitoring (CGM) use results in improved glycemic control in children <8 years of age, many of the barriers to CGM efficacy in this age group may have been due to problems in the wearability and accuracy of prior generation devices, as well as to the setting of glycemic targets aimed primarily at preventing hypoglycemia at all costs. There may also...Mostra di più
Titolo ufficiale
Strategies to Enhance New CGM Use in Early Childhood: A Randomized Clinical Trial to Assess the Efficacy and Safety of Continuous Glucose Monitoring in Youth < 8 With Type 1 Diabetes
Patologie
Diabete mellito di tipo 1Pubblicazioni
Articoli scientifici e documenti di ricerca pubblicati su questo studio clinico:Altri ID dello studio
- SENCE
- T1DX SENCE
Numero NCT
Data di inizio (effettiva)
2017-01-30
Ultimo aggiornamento pubblicato
2020-10-05
Data di completamento (stimata)
2019-06-30
Arruolamento (previsto)
143
Tipo di studio
Interventistico
FASE
N.D.
Stato
Completato
Scopo principale
Terapia di supporto
Allocazione
Randomizzato
Modello di intervento
Fattoriale
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
| Gruppo/Braccio di partecipanti | Intervento/Trattamento |
|---|---|
Comparatore attivoCGM + Family Behavioral Intervention CGM training for CGM groups using a standard curriculum will take place at the 1, 3 and 6 week visits in addition to the training at baseline. The family behavioral intervention will be delivered by a study coordinator (separate coordinator from the CGM instruction) at the 1, 3, 6, 13 and 19 week visits and is expected to take approximately 30 minutes. | CGM + Family Behavioral Intervention use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence |
Comparatore attivoStandard CGM Each participant will be asked to use a CGM sensor on a daily basis, inserting a new sensor as needed with a maximum of 7 days of wear per sensor.
A home BGM will be used for calibration of the CGM sensor. Additional BGM glucose measurements may be performed by the participant at any time, particularly prior to making a real-time management decision based on the CGM glucose reading.
Participants will be instructed ...Mostra di più | Standard CGM use of CGM alone to assess CGM adherence |
Nessun interventoBGM - usual care control group A BGM will be used for a finger stick blood glucose check with a recommendation of at least 4 times a day. BGM data will be downloaded and reviewed with the participant at each visit. | N.D. |
Esito primario
Esito secondario
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Time in glucose range 70-180 | The primary outcome will be three 2 group comparisons of the change from baseline in the percentage of sensor values in the target range (70-180 mg/dL), in an ANCOVA model adjusted for the baseline value and factors used to stratify randomization with clinical site as a random effect. Seven days of sensor glucose values during the week prior to the 6, 13, 19 and 26 week clinic visits will be used in analysis for the CGM groups to match up with the blinded CGM placed at each visit in the control group. The CGM data will be pooled across each visit where CGM data are collected during follow up for the primary analysis. | Up to 26 weeks |
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
HbA1c at 6-months | A secondary outcome is to compare HbA1c at 6-months, adjusted for baseline. | 6 Months |
% HbA1c <7.0% | 6 Months | |
% HbA1c <7.5% | 6 Months | |
% with relative reduction in HbA1c >=10% | 6 Months | |
% with absolute reduction in HbA1c >=0.5% | 6 Months | |
% with absolute reduction in HbA1c >=1% | 6 Months | |
% with absolute reduction in HbA1c >=1% or HbA1c <7.0% | 6 Months | |
Mean glucose | 6 Months | |
Glucose variability measured by coefficient of variation | 6 Months | |
% time >180 mg/dl | 6 Months | |
% time >250 mg/dl | 6 Months | |
% time >300 mg/dl | 6 Months | |
Area under the curve 180 mg/dl | 6 Months | |
High blood glucose index (HBGI) | 6 Months | |
% time <54 mg/dl | 6 Months | |
% time <60 mg/dl | 6 Months | |
% time <70 mg/dl | 6 Months | |
Area over the curve 70 mg/dl | 6 Months | |
Low blood glucose index (LBGI) | 6 Months | |
Hypoglycemic events (using <54 mg/dl) | 6 Months | |
WHO-5 Well Being Index | Survey containing 5 questions with possible responses 0-5. The raw score is calculated by summing the responses. The raw score ranges from 0-25. A percentage score ranging from 0 to 100 is obtained by multiplying the raw score by 4. A percentage score of 0 represents worst possible, whereas a score of 100 represents best possible quality of life. | 6 Months |
Hypoglycemia Fear Survey Total Score | Survey containing 26 questions with possible responses 0-4. Total score is calculated by taking the mean of the non-missing responses and multiplying by 25 to put on the scale 0-100. A higher score indicates more fear. | 6 Months |
Hypoglycemia Fear Survey Worry Subscale | Survey containing 26 questions with possible responses 0-4. Worry subscale score is calculated by taking the mean of the non-missing responses to questions 11-26 and multiplying by 25 to put on the scale 0-100. A higher score indicates more fear. | 6 Months |
Diabetes Technology Questionnaire | Survey containing 30 questions with possible responses 0-4. Total score is calculated by taking the mean of the non-missing responses and multiplying by 100 to put on the scale 0-100. A higher total score indicates less of a problem. | 6 Months |
Problem Areas in Diabetes - Parent (PAID-PR) | Survey containing 18 questions with possible responses 0-4. Total score is calculated by reverse scoring each item, then taking the mean of the non-missing responses. The score is then multiplied by 25 to put on the scale 0-100. A higher total score indicates more burden. | 6 Months |
Diabetes Family Impact Survey | Survey containing 15 questions with possible responses 0-3. Total score is calculated by taking the mean of the non-missing responses. Then multiply by 100 and divide by 3 to put on the scale 0-100. A higher total score indicates more negative impact. | 6 Months |
Satisfaction Questionnaire | Section 2 of the satisfaction questionnaire contains 8 questions for the CGM groups only with possible responses 0-4. Total score is calculated by taking the mean of the non-missing responses and multiplying by 25 to put on the scale 0-100. A higher total score indicates more satisfaction with the study. | 6 Months |
Criteri di eleggibilità
Età idonea
Bambino
Età minima
2 Years
Sessi idonei
Tutti
- Clinical diagnosis of insulin dependent presumed autoimmune type 1 diabetes by the investigator
- Age 2-<8 years at consent
- Diabetes duration ≥ 6 months
- Total daily insulin ≥ 0.3 units per kg per day
- HbA1c 7.0% to <10.0% (Point of care device or local lab measured within 30 days of screening visit used to assess eligibility)
- No use of unblinded personal CGM, outside of a research study, as part of real-time diabetes management in the last 30 days
- Insulin regimen involves either use of a consistent insulin regimen with an insulin pump in the last 3 months or at least 3 multiple daily injections of basal and bolus (meal time) analogue insulin in the last 3 months (e.g. no change from injections to pump or vice versa in the last 3 months), with no plans to switch the modality of insulin administration during the next 6 months (e.g., injection user switching to a pump, pump user switching to injections).
- Perform at least 3 blood glucose meter checks per day from self-report at screening and meter download during blinded CGM run in
- Not currently using and no plans to begin non-insulin medication for blood glucose lowering during the course of the study
- Parent or guardian comprehend written and spoken English (This requirement is due to the fact that the questionnaires to be used as outcome measures do not have validated versions in other languages, and interventions will be delivered in English only for the RCT to ensure standardization/fidelity checks across sites).
- Parent understands the study protocol and agrees to it
- No expectation that participant/parent will be moving out of the area of the clinical center during the next 12 months, unless the move will be to an area served by another study center.
Use of unblinded personal CGM, outside of a research study, as part of real-time diabetes management in the last 30 days
Unable to use CGM device for minimum number of hours during blinded run-in period or skin reaction from adhesive that would preclude participation in the randomized trial
The presence of a significant medical disorder or use of a medication such as oral/inhaled glucocorticoids that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol.
More than 1 episode of SH or DKA in the past 6 months (not including DKA at time of dx).
The presence of any of the following diseases:
- Asthma if treated with systemic or daily inhaled corticosteroids in the last 6 months (Intermittent treatment with inhaled corticosteroids does not exclude subjects from enrollment)
- Cystic fibrosis (Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment)
Inpatient psychiatric treatment in the past 6 months for either child participant or the primary care giver
Need for use of acetaminophen or acetaminophen-containing products on a regular basis during the 6 months of the trial
Participation of parent or child in a diabetes related intervention study in past 6 weeks.
Any medical, psychological or social situation where per investigator discretion it may be difficult for family or child to participate fully in the intervention
Another member of the same household is participating in this study.
Jaeb Center for Health Research- The Leona M. and Harry B. Helmsley Charitable Trust
- Università dell'Indiana285 studi clinici attivi da esplorare
Nessun dato di contatto
1 Centri dello studio in 1 paesi
Indiana
Indiana, Indianapolis, Indiana, 46202, United States